Gilead Sciences acquires German biotech company for $1.39 billion
December 10, 2020 at 11:25 AM EST
The acquisition aims to boost Gilead’s development and commercialization of therapeutics for treating the chronic hepatitis delta virus.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|